Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin after atrial fibrillation ablation in patients with subclinical HFpEF
ACTRN12626000399392Phase 4Not yet recruiting
- Sponsor
- University of Adelaide
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Atrial fibrillation (AFib) and heart failure with preserved ejection fraction (HFpEF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: AF recurrence. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ACTRN12626000399392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000399392.